Cargando…

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions

The oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase selectivity and pharmacokinetics. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhullar, Jasjeet, Natarajan, Karthika, Shukla, Suneet, Mathias, Trevor J., Sadowska, Mariola, Ambudkar, Suresh V., Baer, Maria R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743865/
https://www.ncbi.nlm.nih.gov/pubmed/23967177
http://dx.doi.org/10.1371/journal.pone.0071266
_version_ 1782280532013350912
author Bhullar, Jasjeet
Natarajan, Karthika
Shukla, Suneet
Mathias, Trevor J.
Sadowska, Mariola
Ambudkar, Suresh V.
Baer, Maria R.
author_facet Bhullar, Jasjeet
Natarajan, Karthika
Shukla, Suneet
Mathias, Trevor J.
Sadowska, Mariola
Ambudkar, Suresh V.
Baer, Maria R.
author_sort Bhullar, Jasjeet
collection PubMed
description The oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase selectivity and pharmacokinetics. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Co-administration with chemotherapy is planned. We characterized interactions of quizartinib with the ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Its effects on uptake of fluorescent substrates and apoptosis were measured by flow cytometry, binding to ABCB1 and ABCG2 drug-binding sites by effects on [(125)I]iodoarylazidoprazosin ([(125)I]-IAAP) photolabeling and ATPase activity, and cell viability by the WST-1 colorimetric assay. Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5 µM and from 0.5 to 10 µM, respectively, and inhibited [(125)I]-IAAP photolabeling of ABCG2 and ABCB1 with IC(50) values of 0.07 and 3.3 µM, respectively. Quizartinib at higher concentrations decreased ABCG2, but not ABCB1, ATPase activity. Co-incubation with quizartinib at 0.1 to 1 µM sensitized ABCG2-overexpressing K562/ABCG2 and 8226/MR20 cells to ABCG2 substrate chemotherapy drugs in a concentration-dependent manner in cell viability and apoptosis assays. Additionally, quizartinib increased cellular uptake of the ABCG2 substrate fluoroquinolone antibiotic ciprofloxacin, which also prolongs the QT interval, in a concentration-dependent manner, predicting altered ciprofloxacin pharmacokinetics and pharmacodynamics when co-administered with quizartinib. Thus quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. These interactions should be considered in the design of treatment regimens combining quizartinib and chemotherapy drugs and in choice of concomitant medications to be administered with quizartinib.
format Online
Article
Text
id pubmed-3743865
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37438652013-08-21 The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions Bhullar, Jasjeet Natarajan, Karthika Shukla, Suneet Mathias, Trevor J. Sadowska, Mariola Ambudkar, Suresh V. Baer, Maria R. PLoS One Research Article The oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase selectivity and pharmacokinetics. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Co-administration with chemotherapy is planned. We characterized interactions of quizartinib with the ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Its effects on uptake of fluorescent substrates and apoptosis were measured by flow cytometry, binding to ABCB1 and ABCG2 drug-binding sites by effects on [(125)I]iodoarylazidoprazosin ([(125)I]-IAAP) photolabeling and ATPase activity, and cell viability by the WST-1 colorimetric assay. Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5 µM and from 0.5 to 10 µM, respectively, and inhibited [(125)I]-IAAP photolabeling of ABCG2 and ABCB1 with IC(50) values of 0.07 and 3.3 µM, respectively. Quizartinib at higher concentrations decreased ABCG2, but not ABCB1, ATPase activity. Co-incubation with quizartinib at 0.1 to 1 µM sensitized ABCG2-overexpressing K562/ABCG2 and 8226/MR20 cells to ABCG2 substrate chemotherapy drugs in a concentration-dependent manner in cell viability and apoptosis assays. Additionally, quizartinib increased cellular uptake of the ABCG2 substrate fluoroquinolone antibiotic ciprofloxacin, which also prolongs the QT interval, in a concentration-dependent manner, predicting altered ciprofloxacin pharmacokinetics and pharmacodynamics when co-administered with quizartinib. Thus quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. These interactions should be considered in the design of treatment regimens combining quizartinib and chemotherapy drugs and in choice of concomitant medications to be administered with quizartinib. Public Library of Science 2013-08-14 /pmc/articles/PMC3743865/ /pubmed/23967177 http://dx.doi.org/10.1371/journal.pone.0071266 Text en © 2013 Bhullar et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bhullar, Jasjeet
Natarajan, Karthika
Shukla, Suneet
Mathias, Trevor J.
Sadowska, Mariola
Ambudkar, Suresh V.
Baer, Maria R.
The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
title The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
title_full The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
title_fullStr The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
title_full_unstemmed The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
title_short The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
title_sort flt3 inhibitor quizartinib inhibits abcg2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743865/
https://www.ncbi.nlm.nih.gov/pubmed/23967177
http://dx.doi.org/10.1371/journal.pone.0071266
work_keys_str_mv AT bhullarjasjeet theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT natarajankarthika theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT shuklasuneet theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT mathiastrevorj theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT sadowskamariola theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT ambudkarsureshv theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT baermariar theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT bhullarjasjeet flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT natarajankarthika flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT shuklasuneet flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT mathiastrevorj flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT sadowskamariola flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT ambudkarsureshv flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions
AT baermariar flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions